Tarsus to Participate in Upcoming Investor Conferences
Tarsus (NASDAQ:TARS) announced that management will participate in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference/b] on June 2 at 8:00 a.m. PT / 11:00 a.m. ET and the on June 3 at 8:40 a.m. PT / 11:40 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus (NASDAQ:TARS) announced that management will participate in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference/b] on June 2 at 8:00 a.m. PT / 11:00 a.m. ET and the on June 3 at 8:40 a.m. PT / 11:40 a.m. ET.
Live webcasts, details, and limited-time replays will be available in the events section of the Tarsus website.
Details
News Market Reaction – TARS
On May 29, the first trading day after this news, TARS closed 0.24% below the previous close.
Data tracked by StockTitan Argus for the May 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
- William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 8:00 a.m. PT / 11:00 a.m. ET.
- 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 8:40 a.m. PT / 11:40 a.m. ET.
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.